Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 20–21
HOS-112108 · Präparat HOS-093615
20
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
Fluticasone propionate The fluticasone propionate plasma levels Co-administration of
intranasal 50 μg 4 times daily increased significantly, whereas the REYATAZ/ritonavir and these
for 7 days intrinsic cortisol levels decreased by glucocorticoids metabolised by
(ritonavir 100 mg capsules twice approximately 86% (90% confidence CYP3A4 is not recommended
daily) interval 82%-89%). Greater effects may be unless the potential benefit of
expected when fluticasone propionate is treatment outweighs the risk of
And inhaled. Systemic corticosteroid effects systemic corticosteroid effects
including Cushing’s syndrome and adrenal (see section 4.4).
Inhaled/Nasal Corticosteroids suppression have been reported in patients A dose reduction of the
receiving ritonavir and inhaled or glucocorticoid should be considered
intranasally administered fluticasone with close monitoring of local and
propionate; this could also occur with systemic effects or a switch to a
other corticosteroids metabolised via the glucocorticoid, which is not a
P450 3A pathway, e.g., budesonide. The substrate for CYP3A4 (e.g.,
effects of high fluticasone systemic beclomethasone). Moreover, in case
exposure on ritonavir plasma levels are yet of withdrawal of glucocorticoids,
unknown. The mechanism of interaction is progressive dose reduction may
CYP3A4 inhibition. have to be performed over a longer
period.
Concomitant use of REYATAZ (with or
without ritonavir) and other Inhaled/Nasal Concomitant use of Inhaled/Nasal
Corticosteroids is expected to produce the Corticosteroids and REYATAZ
same effects. (with or without ritonavir) may
increase plasma concentrations of
Inhaled/Nasal corticosteroids. Use
with caution. Consider alternatives
to Inhaled/Nasal Corticosteroids,
particularly for long-term use.
ERECTILE DYSFUNCTION
PDE5 Inhibitors
Sildenafil, tadalafil, vardenafil Sildenafil, tadalafil, and vardenafil are
Patients should be warned about
metabolised by CYP3A4. Co- these possible side effects when
administration with REYATAZ may result
using PDE5 inhibitors for erectile
in increased concentrations of the PDE5
dysfunction with REYATAZ (see
inhibitor and an increase in PDE5-
section 4.4).
Also see PULMONARY
associated adverse events, including
ARTERIAL HYPERTENSION in
hypotension, visual changes, and priapism.
this table for further information
The mechanism of this interaction is
CYP3A4 inhibition. regarding co-administration of
REYATAZ with sildenafil.
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR ANTAGONISTS
Elagolix The mechanism of interaction is Concomitant use of elagolix
anticipated increase in elagolix exposure in 200 mg twice daily with
the presence of CYP3A4 inhibition by REYATAZ (with or without
atazanavir and/or ritonavir. ritonavir) for more than 1 month is
not recommended due to the
potential risk of adverse events
such as bone loss and hepatic
transaminase elevations. Limit
concomitant use of elagolix 150 mg
once daily with REYATAZ (with
or without ritonavir) to 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) elagolix (HOS-112109) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) ritonavir (HOS-084521) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 635c8268586ef0a6549f4f61ffc231edde0b1b51942c8c61e4e49a8f50290b2a · Zeichen 55637–61614 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 56–57
HOS-112197 · Präparat HOS-093615
56
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Fluticasone propionate The fluticasone propionate plasma levels Co-administration of
intranasal 50 μg 4 times daily increased significantly, whereas the REYATAZ/ritonavir and these
for 7 days intrinsic cortisol levels decreased by glucocorticoids metabolised by
(ritonavir 100 mg capsules approximately 86% (90% confidence CYP3A4 is not recommended
twice daily) interval 82%-89%). Greater effects may be unless the potential benefit of
expected when fluticasone propionate is treatment outweighs the risk of
And inhaled. Systemic corticosteroid effects systemic corticosteroid effects
including Cushing’s syndrome and adrenal (see section 4.4).
Inhaled/Nasal Corticosteroids suppression have been reported in patients A dose reduction of the
receiving ritonavir and inhaled or glucocorticoid should be
intranasally administered fluticasone considered with close
propionate; this could also occur with other monitoring of local and
corticosteroids metabolised via the P450 systemic effects or a switch to
3A pathway, e.g., budesonide. The effects a glucocorticoid, which is not a
of high fluticasone systemic exposure on substrate for CYP3A4 (e.g.,
ritonavir plasma levels are yet unknown. beclomethasone). Moreover, in
The mechanism of interaction is CYP3A4 case of withdrawal of
inhibition. glucocorticoids, progressive
dose reduction may have to be
Concomitant use of REYATAZ (with or performed over a longer
without ritonavir) and other Inhaled/Nasal period.
Corticosteroids is expected to produce the
same effects. Concomitant use of
Inhaled/Nasal Corticosteroids
and REYATAZ (with or
without ritonavir) may increase
plasma concentrations of
Inhaled/Nasal corticosteroids.
Use with caution. Consider
alternatives to Inhaled/Nasal
Corticosteroids, particularly for
long-term use.
ERECTILE DYSFUNCTION
PDE5 Inhibitors
Sildenafil, tadalafil, Sildenafil, tadalafil, and vardenafil are
Patients should be warned
vardenafil metabolised by CYP3A4. Co- about these possible side
administration with REYATAZ may result
effects when using PDE5
in increased concentrations of the PDE5
inhibitors for erectile
inhibitor and an increase in PDE5-
dysfunction with REYATAZ
associated adverse events, including
(see section 4.4).
Also see PULMONARY
hypotension, visual changes, and priapism.
ARTERIAL
The mechanism of this interaction is
CYP3A4 inhibition. HYPERTENSION in this table
for further information
regarding co-administration of
REYATAZ with sildenafil.
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR ANTAGONISTS
Elagolix The mechanism of interaction is anticipated Concomitant use of elagolix
increase in elagolix exposure in the 200 mg twice daily with
presence of CYP3A4 inhibition by REYATAZ (with or without
atazanavir and/or ritonavir. ritonavir) for more than
1 month is not recommended
due to the potential risk of
adverse events such as bone
loss and hepatic transaminase
elevations. Limit concomitant
use of elagolix 150 mg once
daily with REYATAZ (with or
without ritonavir) to 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) elagolix (HOS-112109) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) ritonavir (HOS-084521) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 48a34194fe14fdb331f424e7223a33e7800beb55222a98a47e4c5a5060800d73 · Zeichen 57743–64096 im Abschnitt
Wechselwirkungen · Truqap
TRUQAP 160 mg film-coated tablets TRUQAP 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150761 · Präparat HOS-100380
Moderate CYP3A4 inducers
Co-administration of capivasertib with moderate CYP3A4 inducer has the potential to decrease the
concentration of capivasertib. This may reduce the efficacy of TRUQAP. Co-administration of
moderate CYP3A4 inducers should be avoided (e.g. bosentan, cenobamate, dabrafenib, elagolix,
etravirine, lersivirine, lesinurad, lopinavir, lorlatinib, metamizole, mitapivat, modafinil, nafcillin,
pexidartinib, phenobarbital, rifabutin, semagacestat, sotorasib, talviraline, telotristat ethyl,
thioridazine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) phenobarbital (HOS-085617) modafinil (HOS-090546) rifabutin (HOS-086262) thioridazine (HOS-086281) sotorasib (HOS-147831) etravirine (HOS-088088) lesinurad (HOS-141154) dabrafenib (HOS-109452) telotristat ethyl (HOS-141158) mitapivat (HOS-147878) nafcillin (HOS-125452) elagolix (HOS-112109) lorlatinib (HOS-140195) bosentan (HOS-086291) pexidartinib (HOS-150766) cenobamate (HOS-146930)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-06T12:20:00Z · SHA-256 b060cde010dec5d14aa99becadb87be90da15add7354e09540675f70797404c4 · Passage 43e09a1183a46dece579329742c5c42c18ba144104961e5110d22330aa49be6a · Zeichen 1888–2410 im Abschnitt
Wechselwirkungen · Balversa
Balversa 3 mg film-coated tablets Balversa 4 mg film-coated tablets Balversa 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-151047 · Präparat HOS-100442
Strong or moderate CYP3A4 inducers
Co-administration with carbamazepine, a strong CYP3A4 and weak CYP2C9 inducer leads to
decreased erdafitinib exposure. Mean ratios of Cmax and AUC∞ for erdafitinib was 65.4% (90% CI:
60.8, 70.5) and 37.7% (90% CI: 35.4, 40.2), respectively, when co-administered with carbamazepine
relative to erdafitinib alone. Avoid co-administration of Balversa with strong CYP3A4 inducers (such
as apalutamide, enzalutamide, lumacaftor, ivosidenib, mitotane, rifapentine, rifampicin,
carbamazepine, phenytoin, and St. John’s wort). If Balversa is co-administered with a moderate
CYP3A4 inducer (such as dabrafenib, bosentan, cenobamate, elagolix, efavirenz, etravirine, lorlatinib,
mitapivat, modafinil, pexidartinib, phenobarbital, primidone, repotrectinib, rifabutin, sotorasib,
telotristat ethyl), the dose should be cautiously increased by 1 to 2 mg and adjusted gradually every
two to three weeks based on clinical monitoring for adverse reactions, not to exceed 9 mg. If the
moderate CYP3A4 inducer is discontinued, the Balversa dose may be adjusted as tolerated (see
sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) sotorasib (HOS-147831) etravirine (HOS-088088) dabrafenib (HOS-109452) telotristat ethyl (HOS-141158) mitapivat (HOS-147878) mitotane (HOS-112479) elagolix (HOS-112109) lorlatinib (HOS-140195) rifapentine (HOS-116386) ivosidenib (HOS-112046) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531) repotrectinib (HOS-151068) enzalutamide (HOS-116829) pexidartinib (HOS-150766) cenobamate (HOS-146930) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-23T15:29:41Z · SHA-256 9ba94a293568a63e1d68e3b08064d69d982961a4e8105cf8a7ed2e20ea28400b · Passage 37f802579316593a43bdb4de7805a7ac6e6865a9f601ae60d32e15b61a221f1c · Zeichen 1417–2535 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.